Recurrent Malignant Mesothelioma Clinical Trial
Official title:
A Phase II Trial of AMG 102 in Combination With Pemetrexed and Cisplatin in Patients With Malignant Pleural Mesothelioma
This phase II trial is studying how well giving AMG 102 together with pemetrexed disodium and cisplatin works in treating patients with malignant pleural mesothelioma. Monoclonal antibodies, such as AMG 102, can block tumor growth in different ways. Some block the ability of tumor cells to grow or spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving AMG 102 together with pemetrexed disodium and cisplatin may kill more tumor cells
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | May 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically and cytologically confirmed malignant mesothelioma of the pleura - All subtypes allowed - Disease not amenable to curative surgery - Measurable disease - Patients with disease not measurable by standard RECIST criteria (i.e., pleural rinds/thickening only) allowed - Pleural effusions or positive bone scans are not considered measurable - No prior radiotherapy to the target lesion or measurable lesion unless the site has subsequent evidence of progression - Patients who have undergone pleurodesis allowed - Post-pleurodesis CT scan required - No known or suspected brain metastases - ECOG performance status 0-1 - ANC = 1,500/mm^3 - Platelet count = 100,000/mm^3 - Total bilirubin = 1.5 times upper limit of normal (ULN) - Alkaline phosphatase = 1.5 times ULN - ALT and AST = 1.5 times ULN - Albumin = 2.5 g/dL - Creatinine clearance = 45 mL/min OR serum creatinine = 1.5 times ULN - Able to take folic acid and vitamin B12 - Not pregnant or nursing - Negative pregnancy test - Fertile patients must agree to use effective contraception - No active infection or serious concomitant systemic disorder in compatible with the study - No thrombosis or vascular ischemic events within the last 12 months, including any of the following: - Deep venous thrombosis - Pulmonary embolism - Transient ischemic attack - Cerebral infarction - Myocardial infarction - No peripheral edema = grade 3 - No serious or non-healing wounds - No second primary malignancy except in situ carcinoma of the cervix or breast, other in situ malignancies, adequately treated basal cell carcinoma of the skin, or other malignancy within the past 3 years with no evidence of recurrence - No concurrent antiretroviral therapy for HIV-positive patients - At least 4 weeks since prior radiotherapy - More than 30 days since major surgery procedures or > 14 days since any minor surgical procedure and recovered - Central venous catheter placement, fine-needle aspiration, thoracentesis, or paracentesis are not considered major or minor surgical procedures - No prior systemic chemotherapy for mesothelioma - No prior intracavity cytotoxic drugs or immunomodulators (unless for the purpose of pleurodesis) - No prior anti-HGF monoclonal antibody AMG 102, other c-MET, or HGF inhibitors - No prior or concurrent anticoagulation therapy within the past 7 days - Low-dose Coumadin-type anticoagulants or low-molecular weight heparin for prophylaxis against central venous catheter thrombosis allowed - No investigational agents within the past 4 weeks |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival | From registration to clinical evidence of disease progression or death without progression, assessed up to 3 years | No | |
Secondary | Toxicity defined as a grade 4 hemorrhagic event or a grade 5 event | Graded using the NCI CTCAE. | Up to 30 days after completion of study treatment | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00025207 -
Gefitinib in Treating Patients With Malignant Mesothelioma
|
Phase 2 | |
Completed |
NCT00107432 -
Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
|
Phase 2 | |
Terminated |
NCT00028782 -
EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
|
N/A | |
Completed |
NCT00027703 -
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma
|
Phase 2 | |
Recruiting |
NCT04213794 -
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients
|
Early Phase 1 | |
Completed |
NCT01503177 -
Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
|
Phase 1 | |
Completed |
NCT00243074 -
S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT01126346 -
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
|
N/A | |
Completed |
NCT00039182 -
Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
|
Phase 2 | |
Withdrawn |
NCT01325753 -
Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body
|
N/A | |
Completed |
NCT00459862 -
Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
|
Phase 2 | |
Active, not recruiting |
NCT01064648 -
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
|
Phase 1/Phase 2 | |
Completed |
NCT00365053 -
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
|
Phase 2 | |
Terminated |
NCT01861301 -
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
|
Phase 2 | |
Completed |
NCT00392444 -
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
|
Phase 2 | |
Completed |
NCT00309946 -
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00030498 -
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
|
Phase 1 | |
Recruiting |
NCT03420963 -
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
|
Phase 1 |